SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Texas Biotech (TXB)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
834 13 0 TXB
Emcee:  Andrew R. Sicotte Type:  Unmoderated
Introduction Market Data Compact
Anybody following this? It just broke $5 again, near old high. Volume about 1.5 Mil. A breakout?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
834Snip from Wachovia: TXBI: On Tuesday, TXBI and GlaxoSmithKline presented a postmopgcw-4/16/2003
833<i>ICOS-Texas Biotechnology L.P. Announces Phase 2b/3 Trial Results for Sikeokalani'nui-10/21/2002
832Argatroban Found Safe and Effective in Patients With Heparin-Induced Thrombocytokeokalani'nui-9/25/2002
831Actelion Reports Positive RAPIDS-1 Results; Actelion Reports Highly Significant keokalani'nui-8/15/2002
830<<Any guess who will have exciting, maybe late breaker, presentation in MaMiljenko Zuanic-3/22/2002
829Thank you. Very nice find (<i>Decreased mortality and a lack of treatmentkeokalani'nui-3/22/2002
828From EU Stroke conference (May): Reduction in Stroke-Associated Mortality in PaMiljenko Zuanic-3/22/2002
827Study Shows Tracleer Doesn't Avert Hospital Stays for Heart Failure Patientskeokalani'nui-3/19/2002
826Actelion says Tracleer fails an CHF trial objective ZURICH, Feb 7 (Reuters) - Bikeokalani'nui-2/7/2002
825Actelion Tracleer distribution network bypasses traditional wholesale and retailkeokalani'nui-12/5/2001
824Bosentan in The Lancet. WESTPORT, CT (Reuters Health) - Bosentan, a dual endothkeokalani'nui-10/5/2001
823Bosentan approvable. <i>In its approvable letter, the FDA states that tkeokalani'nui-9/18/2001
822Bosentan, from pink sheet. <i>Actelion Tracleer Testicular Toxicity In Rakeokalani'nui-8/28/2001
821Argatroban Competitor Schering seeking Refludan rights from Aventis Last Updatkeokalani'nui-8/20/2001
820Re Bosentan, a few comments. Though I thought the ac would punt until after datkeokalani'nui-8/13/2001
819Friday August 10, 3:13 pm Eastern Time Press Release SOURCE: Actelion Ltd FDAscaram(o)uche-8/10/2001
818Wilder-Thanks very much for your 2 posts to me on TXBI. Your first post to me reJOEBT1-8/2/2001
817JOEBT1. Just to close things off for a while. I've burned some time on ET keokalani'nui-7/16/2001
816Speedel Starts Human Testing With SPP 301, Its Endothelin A Receptor Antagonist keokalani'nui-7/6/2001
815Bosntan for PAH in front of CRDAC 8/9/01. Wilderkeokalani'nui-6/26/2001
814Texas Biotechnology and Revotar Biopharmaceuticals AG Initiate Phase I Study Witkeokalani'nui-6/26/2001
813Nice to have some company. Know that I have 0 medical/scientific knowledge and keokalani'nui-6/22/2001
812Wilder--I'm back in this stock--sold out about a year ago. I find it very diJOEBT1-6/22/2001
811txb3214, though originally designed as the follow-on to sitaxsentan, is the preckeokalani'nui-6/21/2001
810Sorry, confused. It looks like second generation in the ICOS partnership is TBCkeokalani'nui-6/19/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News